Albany, N.Y.-based AngioDynamics won FDA 510(k) clearance for the BioFlo earlier this year, the company said.
Midline catheters provide intravenous access for up to 30 days, longer than peripheral intravenous catheters which need to be replaced every few days, the company said.
“The BioFlo Midline catheter is a logical extension of the BioFlo product line, bringing the clinically relevant thrombus reduction properties to patients needing shorter term vascular access to deliver infusion therapies. Its increased period of functionality improves patient satisfaction by lowering the number of needle sticks and interruptions to treatment. Similarly, it offers health care providers an expanded range of patient treatment options that help to increase staff efficiency and reduce the overall cost of care. We see BioFlo as the future of intravenous therapy delivery and our customers agree,” senior vice president Chuck Greiner said in prepared remarks.
The BioFlo catheter is indicated for up to 30-days of peripheral access for intravenous therapy including the administration of fluids, medications and nutrients, sampling of blood and for power injections of contrast media, the company said.
“BioFlo product line sales grew at a double-digit rate last fiscal year and the Midline’s launch, along with continued account wins and market penetration, position us for additional solid BioFlo growth this fiscal year,” CEO Joseph DeVivo said in a press release.
In July, German medical laser maker Biolitec (ETR:BIB) asked the U.S. Supreme Court to review an appeals court decision upholding a $75 million contempt penalty in its longtime legal dispute with AngioDynamics.